查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574767

糖尿病腎臟病市場：按糖尿病類型、藥物類別、最終用戶、給藥途徑- 全球預測 2025-2030

Diabetic nephropathy Market by Diabetes Type, Drug Class (Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers), End-Use, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年糖尿病腎臟病市場價值為27.9億美元，預計到2024年將達到29.3億美元，複合年成長率為6.13%，預計到2030年將達到42.3億美元。

糖尿病腎臟病是糖尿病的嚴重併發症，其特徵是腎臟損害導致末期腎病變。該市場包括診斷測試、治療和疾病管理解決方案。由於全球糖尿病盛行率上升和人口老化，糖尿病腎病變的盛行率不斷上升，因此需要解決糖尿病腎臟病。治療具有廣泛的應用，從藥物干預到監測設備和個人化治療計劃的技術進步。最終用途包括醫院、診所、研究機構和居家醫療環境。影響市場的關鍵成長要素包括生物技術和個人化醫療的進步、醫療保健服務的改善以及政府支持糖尿病管理計劃的舉措。此外，意識的提高和官民合作關係也有助於市場成長。潛在的治療機會在於開發針對糖尿病腎臟病潛在病理學機制的新治療方法，以及將人工智慧整合到早期診斷和個人化治療中。

主要市場統計
基準年[2023] 27.9億美元
預測年份 [2024] 29.3億美元
預測年份 [2030] 42.3億美元
複合年成長率（%） 6.13%

然而，市場成長面臨限制和挑戰，例如先進治療的高成本、新興國家的認知度低以及嚴格的監管核准延遲了產品市場進入。為了利用新的商機，公司應該投資於創新且具有成本效益的治療解決方案的研發，並利用數位健康技術的創新來增強疾病管理和患者依從性。與醫療保健提供者合作開發綜合護理模式可以進一步擴大市場範圍。理想的創新領域包括基因治療、使用生物標記進行早期檢測以及奈米藥物傳輸系統的開發。考慮到市場的性質，該市場競爭激烈，重點是持續研究和協作努力來解決未滿足的需求。為了實現永續成長，企業必須專注於創造負擔得起的、高影響力的解決方案，並培養與學術和研究機構的夥伴關係，以在不斷變化的情況中保持領先地位。

市場動態：揭示快速發展的糖尿病腎臟病市場的關鍵市場洞察

供需的動態交互作用正在改變糖尿病腎臟病變市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 糖尿病和慢性腎臟病盛行率的增加推動了對糖尿病腎臟病變治療的需求
    • 醫療技術和治療方案的進步可改善糖尿病腎臟病變市場的患者預後
    • 增加醫療支出和政府努力支持糖尿病腎臟病新治療方法的開發
    • 提高患者和醫療保健提供者對糖尿病腎臟病早期診斷和管理的認知
  • 市場限制因素
    • 糖尿病腎臟病變有效治療方案的可用性有限且高成本
    • 糖尿病腎臟病變長期管理增加患者的醫療費用和經濟負擔
  • 市場機會
    • 整合人工智慧和機器學習以進行高級診斷和風險分層
    • 投資病患教育計畫以提高自我管理和治療依從性
    • 與科技公司建立策略夥伴關係關係，開發先進的診斷工具
  • 市場問題
    • 糖尿病腎臟病市場的創新：透過先進的治療方法解決未滿足的臨床需求
    • 克服糖尿病腎臟病市場挑戰的策略方法：病患教育與依從性議題

波特五力：駕馭糖尿病腎臟病市場的策略工具

波特的五力框架是了解糖尿病腎臟病市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解糖尿病腎臟病市場的外部影響

外部宏觀環境因素在塑造糖尿病腎臟病市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解糖尿病腎臟病市場的競爭格局

糖尿病腎臟病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣糖尿病腎臟病市場供應商的績效評估

FPNV定位矩陣是評估糖尿病腎臟病市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製糖尿病腎臟病變市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對糖尿病腎臟病市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病和慢性腎臟病盛行率的增加增加了對糖尿病腎臟病變治療的需求。
      • 隨著醫療技術和治療方案的進步改善患者的治療效果，糖尿病腎臟病變市場
      • 醫療成本上升和政府支持新治療方法開發的努力
      • 患者和醫療保健專業人員對糖尿病腎臟病早期診斷和治療的意識不斷增強
    • 抑制因素
      • 糖尿病腎臟病的有效治療選擇有限且成本高昂
      • 長期管理增加病患的醫療費用和經濟負擔
    • 機會
      • 整合人工智慧和機器學習以進行高級診斷和風險分類
      • 投資病患教育計畫以增強自我管理和治療依從性
      • 與科技公司建立策略夥伴關係，開發先進的診斷工具
    • 任務
      • 糖尿病腎臟病市場的創新：透過先進治療方法解決未滿足的臨床需求
      • 克服糖尿病腎臟病市場挑戰的策略方法：病患教育與依從性議題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 糖尿病腎臟病市場：依糖尿病類型

  • 介紹
  • 1型糖尿病
  • 2型糖尿病

第7章 糖尿病腎臟病市場：依藥物類別

  • 介紹
  • 血管收縮素II 受體拮抗劑 (ARB)
  • 血管收縮素轉化酵素(ACE) 抑制劑
  • 鈣離子通道阻斷劑
  • 利尿劑

第8章糖尿病腎臟病市場：依最終用途分類

  • 介紹
  • 診所
  • 透析中心
  • 居家醫療
  • 醫院

第9章糖尿病腎臟病市場：依給藥途徑

  • 介紹
  • 靜脈
  • 口服
  • 皮下的

第10章北美及南美糖尿病腎臟病市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太糖尿病腎臟病市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲糖尿病腎臟病市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vertex Pharmaceuticals 以 49 億美元收購 Alpine Immune Sciences，以加強腎臟疾病治療產品組合併引領 IgAN 市場
    • Sun Pharma 和拜耳合作在印度銷售Finerenone，改善糖尿病腎臟病患者的治療機會和治療結果
    • FDA核准Jardiance治療成人慢性腎臟病，在關鍵 III 期試驗中將進展風險降低 28%
  • 戰略分析和建議
Product Code: MRR-81515600A188

The Diabetic nephropathy Market was valued at USD 2.79 billion in 2023, expected to reach USD 2.93 billion in 2024, and is projected to grow at a CAGR of 6.13%, to USD 4.23 billion by 2030.

Diabetic nephropathy, a severe complication of diabetes, is characterized by kidney damage leading to end-stage renal disease. Its market encompasses diagnostic tests, therapeutics, and disease management solutions. The necessity of addressing diabetic nephropathy arises from its increasing prevalence, driven by the global rise in diabetes rates and an aging population. Applications range from pharmaceutical interventions to technological advancements in monitoring devices and personalized treatment plans. The end-use scope includes hospitals, clinics, research institutions, and home healthcare settings. Key influencing growth factors in the market include advancements in biotechnology and personalized medicine, the increasing accessibility of healthcare services, and government initiatives supporting diabetes management programs. Additionally, rising awareness and public-private partnerships contribute to market growth. Potential opportunities lie in the development of novel therapies targeting the underlying pathophysiological mechanisms of diabetic nephropathy, as well as the integration of artificial intelligence in early diagnosis and treatment personalization.

KEY MARKET STATISTICS
Base Year [2023] USD 2.79 billion
Estimated Year [2024] USD 2.93 billion
Forecast Year [2030] USD 4.23 billion
CAGR (%) 6.13%

However, market growth faces limitations and challenges such as the high cost of advanced treatments, limited awareness in developing countries, and stringent regulatory approvals that delay product market entry. To capitalize on emerging opportunities, businesses should invest in R&D for innovative, cost-effective treatment solutions and leverage digital health technology innovations that enhance disease management and patient compliance. Collaboration with healthcare providers for comprehensive care models could further expand market reach. The best areas for innovation include gene therapy, the use of biomarkers for early detection, and the development of nano-based drug delivery systems. Insights into the market's nature reveal it as highly competitive, with ongoing research and a focus on collaborative efforts to address unmet needs. For sustainable growth, businesses should focus on creating affordable, high-impact solutions and fostering partnerships with academic and research institutions to stay ahead in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic nephropathy Market

The Diabetic nephropathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes and chronic kidney disease driving the demand for Diabetic nephropathy treatments
    • Advancements in medical technology and treatment options improving patient outcomes in the Diabetic nephropathy market
    • Rising healthcare expenditures and government initiatives supporting the development of new Diabetic nephropathy therapies
    • Growing awareness about early diagnosis and management of Diabetic nephropathy among patients and healthcare providers
  • Market Restraints
    • Limited availability and high cost of effective treatment options for diabetic nephropathy
    • Increasing healthcare costs and economic burden on patients for long-term diabetic nephropathy management
  • Market Opportunities
    • Integrating artificial intelligence and machine learning for advanced diagnosis and risk stratification
    • Investing in patient education programs to enhance self-management and treatment adherence
    • Establishing strategic partnerships with technology companies for developing advanced diagnostic tools
  • Market Challenges
    • Innovating in the diabetic nephropathy market: addressing unmet clinical needs through advanced therapeutics
    • Strategic approaches to overcoming challenges in the diabetic nephropathy market: patient education and adherence issues

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic nephropathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic nephropathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic nephropathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic nephropathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic nephropathy Market

A detailed market share analysis in the Diabetic nephropathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic nephropathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic nephropathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic nephropathy Market

A strategic analysis of the Diabetic nephropathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic nephropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen, AstraZeneca, Bayer, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Dexcom, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda Pharmaceutical, and Teva Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Diabetic nephropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diabetes Type, market is studied across Type 1 Diabetes and Type 2 Diabetes.
  • Based on Drug Class, market is studied across Angiotensin II Receptor Blockers (ARBs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, and Diuretics.
  • Based on End-Use, market is studied across Clinic, Dialysis Centers, Home Care, and In Hospital.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and chronic kidney disease driving the demand for Diabetic nephropathy treatments
      • 5.1.1.2. Advancements in medical technology and treatment options improving patient outcomes in the Diabetic nephropathy market
      • 5.1.1.3. Rising healthcare expenditures and government initiatives supporting the development of new Diabetic nephropathy therapies
      • 5.1.1.4. Growing awareness about early diagnosis and management of Diabetic nephropathy among patients and healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability and high cost of effective treatment options for diabetic nephropathy
      • 5.1.2.2. Increasing healthcare costs and economic burden on patients for long-term diabetic nephropathy management
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating artificial intelligence and machine learning for advanced diagnosis and risk stratification
      • 5.1.3.2. Investing in patient education programs to enhance self-management and treatment adherence
      • 5.1.3.3. Establishing strategic partnerships with technology companies for developing advanced diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Innovating in the diabetic nephropathy market: addressing unmet clinical needs through advanced therapeutics
      • 5.1.4.2. Strategic approaches to overcoming challenges in the diabetic nephropathy market: patient education and adherence issues
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic nephropathy Market, by Diabetes Type

  • 6.1. Introduction
  • 6.2. Type 1 Diabetes
  • 6.3. Type 2 Diabetes

7. Diabetic nephropathy Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Angiotensin II Receptor Blockers (ARBs)
  • 7.3. Angiotensin-Converting Enzyme (ACE) Inhibitors
  • 7.4. Calcium Channel Blockers
  • 7.5. Diuretics

8. Diabetic nephropathy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Clinic
  • 8.3. Dialysis Centers
  • 8.4. Home Care
  • 8.5. In Hospital

9. Diabetic nephropathy Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Americas Diabetic nephropathy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Diabetic nephropathy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Diabetic nephropathy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Vertex Pharmaceuticals to acquire Alpine Immune Sciences for USD 4.9 billion, boosting kidney disease treatment portfolio and leading IgAN market.
    • 13.3.2. Sun Pharma and Bayer collaborate to distribute Finerenone in India, boosting access and patient outcomes for CKD in diabetes
    • 13.3.3. FDA approves Jardiance for chronic kidney disease in adults, lowing risk progression by 28% in major phase III trial
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Biocon
  • 6. Boehringer Ingelheim
  • 7. Bristol-Myers Squibb
  • 8. Dexcom
  • 9. Eli Lilly
  • 10. GlaxoSmithKline
  • 11. Johnson & Johnson
  • 12. Medtronic
  • 13. Merck & Co.
  • 14. Novartis
  • 15. Novo Nordisk
  • 16. Pfizer
  • 17. Roche
  • 18. Sanofi
  • 19. Takeda Pharmaceutical
  • 20. Teva Pharmaceutical

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEPHROPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEPHROPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DIABETIC NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DIABETIC NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEPHROPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEPHROPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY IN HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIABETIC NEPHROPATHY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DIABETIC NEPHROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DIABETES TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM DIABETIC NEPHROPATHY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. DIABETIC NEPHROPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. DIABETIC NEPHROPATHY MARKET, FPNV POSITIONING MATRIX, 2023